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Summary 
1    This study has investigated the mechanisms of the acute vasodilator action of bacterial 
lipopolysaccharide (LPS) in the rat Langendorff perfused heart. 
 
2    Infusion of LPS (5 µg/ml) caused a rapid and sustained fall in coronary perfusion 
pressure (PP) of 59 ± 4 mmHg (n = 12) and a biphasic increase in NO levels determined in 
the coronary effluent by chemiluminescent detection. Both the fall in PP and the increase in 
NO release were completely abolished (n = 3) by pre-treatment of hearts with the NO 
synthase inhibitor L-NAME (50 µM). 
 
3    LPS-induced vasodilatation was markedly attenuated to 5 ± 4 mmHg (n = 3) by pre-
treatment of hearts with the B2 kinin receptor antagonist HOE 140 (100 nM). 
 
4    Vasodilator responses to LPS were also blocked by brief pre-treatment with mepacrine 
(0.5 µM, n = 3) or nordihydroguaiaretic acid (0.1 µM, n = 4) and markedly attenuated by 
WEB 2086 (3 μM, n=4).  
 
5    30 min pre-treatment of hearts with dexamethasone (1 nM), but not progesterone (1 μM), 
significantly modified responses to LPS. The action of dexamethasone was time dependent, 
having no effect when applied either simultaneously with or pre-perfused for 5 min prior to 
administration of LPS but inhibiting the response to LPS by 91 ± 1% (n = 4) when pre-
perfused for 15 min.  The inhibition caused by dexamethasone was blocked by 15 min pre-
treatment with the glucocorticoid receptor antagonist RU-486 (100 nM) or by 2 min pre-
perfusion of a 1:200 dilution of LCPS1, a selective anti-LC 1 neutralising antibody.  
6    Treatment with the protein synthesis inhibitor,  cycloheximide (10 µM, for 15 min) 
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selectively blunted LPS-induced vasodilatation, reducing the latter to 3 ± 5 mmHg (n = 3) 
while having no effect on vasodilator responses to either bradykinin or sodium nitroprusside. 
 
7    These results indicate that LPS-induced vasodilatation in the rat heart is dependent on 
activation of kinin B2 receptors and synthesis of NO. In addition, PLA2 is activated by LPS 
resulting in the release of PAF and  lipoxygenase but not cyclo-oxygenase products. These 
effects are dependent on de novo synthesis of an intermediate protein which remains to be 
identified. 
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Introduction 
Nitric oxide (NO) synthesised by inducible NO synthase has been identified as an 
important mediator of the marked hypotension and hyporeactivity to vasoconstrictor agents 
induced by bacterial lipopolysaccharide (LPS) in experimental models of endotoxemia 
(Kilbourn et al., 1990; Thiemermann & Vane, 1990). Although the role of constitutive NO 
synthase in this disease state still remains to be established, it has become apparent that LPS 
may also activate this pathway (Thiemermann & Vane, 1990) with the released NO 
accounting, at least in part, for the initial fall in mean arterial  pressure observed in vivo.  In 
this regard we have previously demonstrated that infusion of LPS through the rat isolated 
perfused heart causes a rapid fall in coronary perfusion pressure (Baydoun et al., 1993). This 
acute vasodilator response was endothelium-dependent and blocked by inhibitors of nitric 
oxide (NO) synthase including L-NG-nitro-L-arginine methylester (L-NAME), strongly 
suggesting that LPS acutely releases NO, presumably via the constitutive L-arginine-NO 
pathway.  
 
We have now extended these studies by examining whether LPS activates constitutive NO 
synthase directly or via intermediate pathways. It is worth noting that both bradykinin and 
platelet activating factor (PAF) may be released acutely following administration of LPS in 
vivo (Doebber et al., 1985; Katori et al., 1989). Furthermore, PAF produces a similar in vivo 
hypotensive response to that caused by LPS (Bessin et al., 1983; Doebber et al., 1985; 
Mulder et al., 1993) and both bradykinin and PAF antagonists have been reported to 
attenuate the acute hypotensive response to LPS (Doebber et al., 1985; Wilson et al., 1989). 
We have therefore examined the effects of the potent and selective kinin B2 receptor 
antagonist D-Arg-[Hyp3, Thi5, D-Tic7, Oic8] bradykinin (HOE-140) (Lembeck et al., 1991) 
and the PAF antagonist WEB 2086 (Casals-Stenzel et al., 1986) on LPS-induced 
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vasodilatation in the rat isolated perfused heart. We have also examined the role of PLA2-
derived mediators other than PAF in the response to LPS.  
 
In our previous study (Baydoun et al., 1993) dexamethasone (10 µM) completely 
abolished the acute coronary vasodilatation caused by LPS. This finding was of interest 
because dexamethasone has previously only been shown to inhibit expression  of the 
inducible isoform of NO synthase whilst having no effect on the constitutive enzyme or the 
activity of inducible NO synthase once expressed (Radomski et al., 1990). We have therefore 
further examined this finding by investigating both the concentration and time dependency of 
the action of dexamethasone and its antagonism by the glucocorticoid receptor antagonist, 
RU-486. Using a selective lipocortin 1 (LC1)-neutralising antibody, LCPS1 (Perretti et al., 
1996), we have explored whether the actions of dexamethasone are mediated by LC1, a 
member of the annexin family which is strongly induced by glucocorticoids and accounts, at 
least in part, for the pharmacological actions of dexamethasone (Flower & Rothwell, 1994). 
 
Methods 
Isolation and perfusion of rat heart 
Hearts from male Sprague-Dawley rats (≥ 250g) were perfused as described previously 
(Baydoun et al., 1993) by a modified Langendorff technique similar to that described by 
Broadley (1979) at a constant flow of 10 ml.min-1 with Krebs-Henseleit buffer (composition 
(mM): NaCl, 118; NaHCO3, 25; D-glucose, 11; KCl, 4.7; MgSO4, 1.2; KH2PO4, 1.1) 
maintained at 37 ºC and gassed with 95 % O2/5% CO2. Following an equilibration period of 
at least 20 min, basal coronary vascular tone (56 ± 4 mmHg; n = 12) was elevated (113 ± 8 
mmHg; n=12) by infusion of the thromboxane mimetic 9,11-dideoxy-11α,9α-epoxymethano- 
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prostaglandin F2α (U46619; 5 nM). Bolus injections of bradykinin (0.1 nmol) or sodium 
nitroprusside (SNP; 10 nmol) were administered into the perfusion line 3 cm proximal to the 
heart. All other agents, including LPS, were added to the buffer reservoir and perfused 
through the coronary vasculature. 
 
Chemiluminescent detection of nitric oxide  
Release of NO into the coronary effluent was monitored by chemiluminescent detection 
using a Sievers NO analyser (model 280A, Sievers instruments Inc. Boulder CO, USA), as 
previously described (Menon et al., 1989). In these studies, coronary flow was reduced to 1 
ml min-1 in order to concentrate amounts of nitrite/nitrate released into the effluent. This was 
carried out in a stepwise manner by reducing flow from 10 to 8, 5, 3 and 1 ml.min-1, allowing 
the heart to equilibrate for 10 min at each reduced flow rate. This protocol did not result in 
any impairment of myocardial function, since when flow was restored to 10 ml.min-1, cardiac 
contractility,  vascular tone and heart rate returned to their normal values prior to reducing 
flow.  
 
After equilibration at 1 ml min-1 aliquots of effluent (0.5 ml) were collected prior to 
(control sample) and at approximately 3 min intervals following perfusion of LPS (5 μg ml-1) 
over a period of 60 min. In time-matched controls hearts were perfused with Krebs buffer 
alone. Samples were immediately frozen at -20 ºC until analysed. Nitrite and nitrate, the 
stable oxidation products of NO in the heart (Kelm & Schrader, 1990), were converted to NO 
by injecting  2-10 μl of effluent into a vessel containing a reducing solution of vanadium(III) 
chloride in HCl. Liberated NO was then purged from solution by bubbling with nitrogen 
under reduced pressure and analysed by reaction with ozone. This reaction yields light, the 
intensity of which was recorded using a cooled red-sensitive photomultiplier tube. The 
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integral of light intensity with respect to time is proportional to the amount of NO yielded 
from the sample injection. A calibration  curve was constructed using standard solutions of 
sodium nitrate in water and used to determine NO concentration in coronary effluent 
samples. Each sample was analysed in triplicate. 
 
Materials 
Salts for Krebs buffer and hydrochloric acid were obtained from British Drug House Ltd. 
(Poole, Dorset). U46619, bacterial lipopolysaccharide (from E. coli, serotype 0111:B4), 
bradykinin, cycloheximide, L-NG-nitro-L-arginine methyl ester, nordihydroguaiaretic acid 
and sodium nitroprusside were obtained from Sigma Chemical Co. (Poole, Dorset, UK). 
Vanadium(III)chloride was from Fluka Ltd. (Gillingham, Dorset, UK). RU-486 and anti-LC1 
antibodies (LCPS1 and LCPS2) were gifts from Professor R. Flower (William Harvey 
Institute, London, UK). HOE-140 and WEB 2086 were respective gifts from Hoechst 
(Mannheim, Germany) and Dr. G. Cirino (University of Naples; Italy). 
 
Statistical analysis 
Results are expressed as mean ± s.e. mean for n experiments. Statistical analyses were 
performed using a multiple means comparison test (Harper, 1984) validated by comparison 
with the Newman-Keuls multiple range test in the statistical package SPP (Royston, 1984) 
with the overall confidence levels set at 99% (0.01). 
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Results 
Involvement of nitric oxide in LPS-induced coronary vasodilatation 
Consistent with our previous studies (Baydoun et al., 1993), LPS (5 µg.ml-1) caused a 
rapid fall in perfusion pressure (PP) of 59 ± 4 mmHg (n=12). This response was maximal 
within 5 minutes and maintained over a prolonged period (> 90 min) during continued LPS 
infusion.  In parallel experiments, chemiluminescent analysis of coronary effluent revealed a 
marked increase in NO release 3 min after introducing LPS and by 6 min this had declined 
again, but was still higher than basal values (Fig 1). Moreover, NO production was 
maintained at the lower plateau level over the 60 min period of LPS perfusion. No significant 
change above basal was detected in effluent collected from hearts perfused with Krebs buffer 
alone. 
 
 Termination of LPS infusion resulted in rapid reversal of the vasodilator response, with 
vascular tone returning to the pre-LPS level within 3 min after cessation of LPS perfusion. 
Stimulated NO production also decreased rapidly to basal levels following LPS washout. In 
addition, perfusion of hearts with L-NAME (50 µM) abolished the vasodilator response and 
release of NO caused by LPS, but did not alter the response to SNP and reduced the duration 
but not the magnitude of the response to bradykinin (Table 1).  
 
Effects of HOE-140 on LPS-induced vasodilatation 
Pre-perfusion of hearts with the selective kinin B2 receptor antagonist HOE-140 (100 nM) 
caused a small but significant increase in PP of 19 ± 8 mmHg (n = 3; p < 0.05). More 
importantly, HOE pre-treatment completely abolished the vasodilator response to a maximal 
concentration of bradykinin (0.1 nmol) and markedly attenuated LPS-induced vasodilatation, 
reducing the latter by 92 ± 6 % (n=3). In contrast, HOE-140 had no effect on the 
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vasodilatation induced by SNP (10 nmol) confirming its selectivity of action (Fig 2). 
 
Role of PLA2,  PAF and lipoxygenase products in LPS-induced vasodilatation 
     Experiments were carried out employing mepacrine, an effective but non-selective 
inhibitor of  PLA2 , to ascertain whether activation of PLA2 also contributes to the response to 
LPS. In these studies, mepacrine (0.5 μM, 30 min pre-perfusion) selectively blocked LPS-
induced vasodilatation but had no direct effect on coronary tone or on the magnitude and 
duration of responses to either bradykinin (0.1 nmol) or SNP (10 nmol) (Table 2).  
 
We have previously shown that indomethacin has no significant effect on the acute actions 
of LPS in the rat heart (Baydoun et al., 1993), current studies were therefore focused on other 
PLA2-dependent pathways. Studies involving PAF itself proved difficult to interpret for 
several reasons. Firstly, responses to PAF were quite variable. Secondly, a single 
administration of PAF, even at very low doses (10-21 to 10-7 mol), resulted in marked and 
rapid desensitisation to subsequent applications (data not shown). However, experiments 
carried out using the PAF receptor antagonist WEB 2086 revealed that LPS-induced 
vasodilatation was at least in part PAF dependent, since it was attenuated by WEB 2086. A 
30 min pre-perfusion of hearts with WEB 2086 (3 μM) reduced the LPS-induced fall in PP 
by 70 ± 8% (n = 4) whilst having no effect on coronary tone or on either bradykinin (0.1 
nmol) or SNP (10 nmol) induced vasodilatation (Table 2).  
 
In contrast to indomethacin, pre-perfusion of hearts with nordihydroguaiaretic acid 
(NDGA), an inhibitor of lipoxygenase enzymes (Slapke et al., 1983), at a concentration of 
0.1 μM for 30 min, significantly decreased the vasodilator action of LPS in the rat heart.  
Under these conditions, NDGA reduced the LPS-induced fall in PP by 86 ± 5% (n = 4) but 
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failed to modify either bradykinin (0.1 nmol) or SNP (10 nmol) induced changes in vascular 
tone (Table 2). Coronary perfusion pressure was also unaffected by NDGA. 
 
Inhibition of LPS-induced vasodilatation by dexamethasone  
Pre-treatment of hearts with dexamethasone caused marked attenuation of LPS-induced 
vasodilatation at 1 nM and complete inhibition at concentrations of 0.1, 1 and 10 μM. This 
effect was time-dependent: when administered simultaneously with or for 5 min prior to LPS, 
dexamethasone (1 nM) failed to significantly alter the response to LPS; in contrast, pre-
treatment of hearts for 15 or 30 min attenuated the vasodilatation induced by LPS by 92 ± 1 
% (n=3) and 89 ± 3 % (n=3), respectively (Fig. 3). Under similar conditions progesterone 
was without effect even at  1 µM (data not shown).   
 
The inhibition caused by dexamethasone (1 nM, 15 min perfusion) was completely 
blocked when hearts were pre-treated for 15 minutes with the glucocorticoid receptor 
antagonist RU-486 (100 nM) prior to administration of dexamethasone (1 nM). In these 
studies, responses to LPS (5 μg ml-1) were not significantly different from those observed in 
controls (Fig 4).  
 
The role of lipocortin 1 in the inhibitory action of dexamethasone  
To establish whether the action of dexamethasone involves LC1, experiments were 
conducted with a selective polyclonal neutralising anti-LC1 antibody (LCPS1) raised in 
sheep against the N-terminus of LC1 (Perretti et al., 1996). Hearts were pre-perfused for 2 
min with a 1:200 dilution of LCPS1 prior to administration of dexamethasone (1 nM; 15 min) 
and subsequently LPS (5μg.ml-1).  Another sheep anti-lipocortin 1 antibody (LCPS2), which 
recognises the protein but does not neutralise it (Perretti et al., 1996) was used as a control. 
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LCPS1 pre-treatment did not alter vascular tone but markedly attenuated the inhibitory action 
of dexamethasone, restoring LPS-induced vasodilatation to 66 ± 12 % of  the control 
response. The non-neutralising antibody, LCPS2,  was without effect (Fig 4). 
 
Selective inhibition of LPS-induced vasodilatation by cycloheximide 
Since the actions of dexamethasone apparently involved induction of synthesis and/or 
translocation of LC1, we tested the effects of cycloheximide on the LPS-induced fall in 
coronary perfusion pressure. Surprisingly, pre-perfusion of cycloheximide (10µM, 15 min) 
alone completely abolished responses to LPS (5 μg ml-1, Fig.5 ). Thus, further experiments 
involving cycloheximide and dexamethasone could not be carried out. At 10 μM, 
cycloheximide had no effect on basal tone nor did it cause any statistically significant change 
in the responses to either bradykinin (0.1 nmol) or SNP (10 nmol).  
 
Discussion 
These data confirm that perfusion of LPS through rat isolated hearts elicits a rapid and 
maintained vasodilatation. As reported previously (Baydoun et al., 1993) this response is 
blocked by L-NAME, implicating NO as a potential mediator. However, substituted arginine 
analogues such as L-NAME and NG-monomethyl-L-arginine (L-NMMA) can have effects 
other than inhibition of nitric oxide synthase (Cocks & Angus, 1991), and may even cause 
increased release of NO (Archer & Hampi, 1992). To confirm unequivocally whether LPS 
causes NO released from the rat isolated perfused heart we monitored NO production by 
measuring levels of nitrite and nitrate, stable end products of NO metabolism, using 
chemiluminescence detection. These experiments revealed that LPS infusion was 
accompanied by a biphasic increase in release of nitrate and nitrite of which the amounts 
produced over the first 3 min of perfusion are at least six times higher than those maintaining 
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the plateau phase. The reason for the biphasic nature of LPS-induced NO release is not clear. 
There is no correlating biphasic vasodilatation to LPS. However it may be that both the initial 
peak and the plateau of NO production are sufficient to cause maximal and maintained 
dilatation. Since both coronary vasodilatation and NO release were blocked by L-NAME it 
can be concluded that the action of L-NAME in reducing LPS-induced vasodilatation is due 
to inhibition of NO synthesis.  
 
In addition to NO release our study has also implicated bradykinin production in LPS-
induced coronary vasodilatation. This effect is mediated by kinin B2-receptors, since it was 
abolished by HOE 140. These findings are supported by other studies demonstrating that 
bradykinin antagonists block the acute phase of LPS-induced hypotension in vivo (Katori et 
al., 1989; Wilson et al., 1989), and inhibit the rapid release of NO from cultured endothelial 
cells exposed to LPS (Fleming et al., 1992). Further studies in rats deficient in kininogens, 
the physiological precursor of bradykinin, have revealed that the hypotensive response to 
exogenous bradykinin was unchanged, but the biphasic response to LPS was markedly 
altered in that the second, phase (70-80 min after LPS) was conserved, but the first phase 
(~15 min after LPS) was abolished. The same profile of inhibition was seen following HOE 
140-treatment  in kininogen-replete rats (Ueno et al., 1995). Thus bradykinin is an important 
mediator of the acute vasodilator response to LPS and may be released locally following 
stimulation.  
 
Although the precise mechanism of action of bradykinin still remains to be established, it 
is evident that its vasodilator action in the rat heart is mediated, at least in part, via NO 
synthesis following activation of  endothelial constitutive NO synthase (Baydoun & 
Woodward, 1991). Thus, LPS-induced NO production in this study may be secondary to the 
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release of bradykinin since both responses are abolished  by HOE 140. Interestingly, L-
NAME completely abolished vasodilatation to LPS but only partially inhibited responses to 
exogenous bradykinin, reducing the duration while having no significant effect on the 
magnitude of the response. This observation is consistent with the hypothesis that exogenous 
bradykinin exerts a biphasic effect in the rat heart of which only the second phase is NO 
mediated (Baydoun & Woodward, 1991). Furthermore, our findings raise the possibility that 
the effects of endogenous and exogenous bradykinin may be mediated differently. In this 
regard, Hecker et al. (1993; 1995) have reported that in endothelium-intact rings of bovine 
coronary artery, another inhibitor of NO synthase L-Nω-nitro-L-arginine (L-NOARG) only 
partially blocked dilator responses to exogenous bradykinin. However in the same 
experiments, the vasodilator effects of moexiprilat and ramiprilat, which act by preventing 
the breakdown of endogenous bradykinin and thus unmasking its dilator effects, were 
completely blocked by L-NOARG. Further studies are clearly required to elucidate the 
mechanism(s) associated with the actions of both exogenous and endogenous kinins.  
 
In addition to the established involvement of NO, additional data obtained with mepacrine, 
WEB 2086 and NDGA suggest that the acute vasodilator response to LPS is complex and 
dependent on multiple mediators. Although the precise link remains to be established, it is 
evident from our data that both the NO synthase and PLA2  pathways are involved. The 
inhibition of LPS-induced vasodilatation by relatively low concentrations of mepacrine 
strongly suggests that PLA2 activation contributes to this response. This is further supported 
by data obtained in the presence of dexamethasone which inhibits PLA2  activation in a 
variety of cells and tissues (Burch, 1990; Lilja et al., 1994). In our study pre-perfusion of 
hearts with dexamethasone for as little as 15 min virtually abolished the vasodilator response 
to LPS. Furthermore this effect was observed with concentrations of dexamethasone well 
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below the standard pharmacologically concentrations routinely used. The low concentrations 
required together with the facts that progesterone was without effect and RU 486 blocked the 
actions of dexamethasone strongly suggests that dexamethasone acts via glucocorticoid 
receptors and was not acting non-selectively via changes in membrane fluidity (Gerritsen et 
al., 1991), or simply by competition for LPS binding sites (TahriJouti & Chaby, 1990). 
 
Further studies established that dexamethasone acted via the induction of LC1, since pre-
perfusion of hearts with the anti-LC1 neutralising antibody LCPS1 markedly attenuated the 
inhibitory actions of dexamethasone. This finding supports the hypothesis that LC1 is a 
mediator of the action of glucocorticoids (Flower & Rothwell, 1994) and is in agreement with 
several reports demonstrating that neutralising antibodies to lipocortin reverse many effects 
of glucocorticoids including their ability to inhibit cell trafficking (Perretti et al., 1996), paw 
oedema (Duncan et al., 1993), cell division and differentiation (Croxtall & Flower, 1992) as 
well as the inhibitory action exerted by these steroids on hormone release from the anterior 
pituitary (Taylor et al., 1995). The rapid onset of the response to dexamethasone may indicate 
that, in the rat heart, dexamethasone may either induce the synthesis and/or rapid 
translocation of pre-formed intracellular LC1 to the membrane. Additionally, dexamethasone 
may also increase release of LC1 from plasma membrane bound pools. Such rapid changes in 
cellular LC1 disposition have indeed been reported in other systems (Solito et al., 1994; 
Kaufman et al., 1996).  
 
We have previously shown that indomethacin has no effect on the response to LPS in the 
rat heart (Baydoun et al., 1993) suggesting that vasodilator cyclo-oxygenase products are not 
involved in this response. In this study we have examined the involvement of other PLA2 -
derived mediators, including PAF, in the response to LPS. Administration of PAF to animals 
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causes a similar shock syndrome to LPS (Bessin et al., 1983; Doebber et al., 1985; Mulder et 
al., 1993). Furthermore, PAF release is increased in animals following LPS-administration, 
and PAF antagonism attenuates endotoxin-induced vasodilatation in experimental models of 
shock (Doebber et al., 1985; Redl et al., 1990).  
 
Our data suggest that PAF is a mediator of LPS-induced vasodilatation in the rat isolated 
perfused heart since responses to LPS were significantly reduced by WEB 2086. However, 
LPS may bind directly to and activate PAF receptors without the need for intermediate PAF 
release (Nakamura et al,1992), an effect that presumably would also be prevented by WEB 
2086.  
 
We could not characterise the effects of exogenous PAF in our system. However, other 
authors have reported that exogenous PAF exerts two different effects with low doses 
(10 fmol - 1 pmol) initiating a vasodilator response while higher doses (≥1 pmol) induce 
vasoconstriction (Man et al., 1990). In our limited studies, administration of PAF to freshly 
isolated hearts did cause coronary vasodilatation. However, these responses were not 
reproducible or dose-dependent. 
 
We investigated the role of the lipoxygenase pathway in mediating responses to LPS by 
examining the effect of NDGA on LPS-induced coronary vasodilatation. NDGA selectively 
inhibited the effect of LPS but failed to modify responses to either SNP or bradykinin. 
However, NDGA has been reported to have several other actions including inhibition of 
PLA2 and of PAF release (Lanni & Becker, 1985). Thus we cannot discount the possibility 
that the effects of NDGA in our studies are due to inhibition of PLA2 rather than 
lipoxygenase.  
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Although further studies utilising more selective inhibitors of lipoxygenases are required it 
is worth noting that 5-lipoxygenase has been implicated in the vasodilator action of PAF in 
the rat isolated perfused heart (Hu et al., 1991). The 5-lipoxygenase inhibitor MK-886 
(Gillard et al. 1989; Rouzer et al., 1990) was found to inhibit the response to PAF as was the 
leukotriene (LT) antagonist L-649,923 (Jones et al., 1986) suggesting that the effects of 
exogenous PAF may be mediated via the release of LT, presumably the vasodilator LT, 
LTB4. Thus, it would not be unreasonable to speculate that in our system, LPS acting 
independently on PAF receptors or via the release of PAF itself may activate 5- lipoxygenase 
pathway and presumably release LTB4. Whether products of the lipoxygenase pathway 
interact with constitutive NO synthase is a fascinating question which remains to be 
investigated. Cross-talk between these two pathways would clearly explain the findings that 
inhibitors of either lipoxygenase or NO synthase virtually abolish LPS-induced vasodilatation 
in the rat heart.  
 
One other potential mechanism of action of PAF is the release of NO, via the constitutive 
endothelial L-arginine-NO pathway, which has been shown to contribute to the vasodilator 
actions of PAF in the mesenteric vasculature of the rat (Chiba et al., 1990). Clearly an action 
of PAF via this pathway would account for the abrogation of the LPS response by NOS 
inhibitors as well as PLA2 and PAF antagonists. Thus the release of NO may be the final end 
point of a multifactorial cascade activated by LPS in the coronary microvasculature of the rat. 
This cascade is dependent on rapid synthesis and/or turnover of an intermediate protein 
which may be the coupling link between the LPS receptor and the initiation of bradykinin 
release and/or PLA2 activation. A comparable dependence on protein synthesis has been 
reported by Petitclerc et al. (1994) who showed that rapid interleukin-1-induced 
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vasodilatation in the rabbit isolated mesenteric artery was blocked within 15 minutes by three 
functionally distinct inhibitors of protein synthesis including cycloheximide. The response to 
interleukin-1, like the response to LPS described here, was dependent on activation of PLA2. 
 
In conclusion, our data confirm that endothelial constitutive NO synthase (eNOS) can be 
activated acutely by LPS resulting in the release of NO in sufficient quantities to initiate 
coronary vasodilatation in the rat heart. This end effect also involves other intracellular 
events including activation of PLA2, which may in turn interact with eNOS via the release of 
PAF. These findings implicate eNOS in the vasodilatation which occurs in LPS-induced 
shock in both experimental models and man. However, these results may have other 
important implications with the acute activation of coronary vasodilatory pathways having 
beneficial cardioprotective rather than the deleterious effects normally associated with 
inflammatory responses induced by endotoxin. This applies in particular to the phenomenon 
of "cross tolerance" induced by endotoxin against ischaemia-reperfusion injury (Song et al., 
1996).  
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Fig 1. LPS induced NO release from the rat isolated perfused heart. Hearts were 
isolated and perfused as described in methods. Following treatment with U46619, 
flow was reduced sequentially to 1 ml.min-1. Coronary effluent was collected in 0.5 
ml aliquots prior to and at 3 min intervals throughout infusion of LPS. Nitrite and 
nitrate levels in samples were determined by chemiluminescent detection using a 
Sievers NO analyser (model 280A, Sievers instruments Inc. Boulder CO, USA) as 
described in methods. Bars represents NO levels detected prior to (basal), 3 min 
(peak) and 6 min (plateau) after LPS perfusion and 30 min after LPS washout. The 
data are the mean ± s.e.mean from 5 separate experiments . * P<0.01 relative to basal 
levels.
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Fig 2. Effect of HOE-140 on vasodilator responses to bradykinin, SNP and LPS. 
Hearts were perfused as described in methods. Responses to bolus injection of 
bradykinin (0.1 nmol) and SNP (10 nmol) were obtained prior to (control) and 
following a 30 min treatment of hearts with 100 nmol.l-1 HOE-140.  LPS (5 µg.ml-1) 
was administered after pretreatment with HOE-140 (100 nmol.l-1) and compared to 
responses observed in separate hearts in the absence of the antagonist. Each bar graph 
represents the mean ± s.e.mean from 3 experiments.  * denotes statistical 
significance at P<0.01  compared to respective controls. 
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Fig 3. Time-course of dexamethasone-induced inhibition of LPS-induced vasodilatation. 
Hearts were perfused as in methods. Dexamethasone (1 nM) was administered either 
simultaneously with or pre-perfused for 5, 15 or 30 min prior to administration of LPS 
(5 µg.ml-1). The data represents mean ± s.e.mean from 3 experiments.  * denotes statistical 
significance at P<0.01 compared to the control LPS response. 
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Fig 4. Effects of RU-486 and anti lipocortin antibodies on dexamethasone-induced 
inhibition of LPS-initiated vasodilatation. Hearts were perfused as in methods. RU486 was 
administered for 15 min prior to perfusion of dexamethasone (Dex; 1nM, 15 min) and 
subsequently LPS (5 μg.ml-1). LCPS1 or LCPS2 (1:200 dilution) were applied for 2 min prior 
to administration of dexamethasone and then LPS. Each bar graph represents mean ± 
s.e.mean from 3 separate experiments. * denotes statistical significance at P<0.01 compared 
to the control LPS response. 
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Fig 5.  Effect of  cycloheximide on vasodilator responses to bradykinin, SNP and LPS. 
Hearts were perfused as in methods. Responses to bolus injection of bradykinin (0.1 nmol) 
and SNP (10 nmol) were obtained prior to (controls) and following a 15 min treatment of 
hearts with cycloheximide (10 µM). LPS (5 µg.ml-1) was administered after pretreatment 
with cycloheximide and compared to responses observed in separate hearts in the absence of 
the inhibitor. Each bar graph represents mean + s.e.mean from 3 experiments.  * denotes 
statistical significance at P<0.01  compared to respective controls. 
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Table 1. Effects of L-NAME treatment on responses to bradykinin, sodium 
nitroprusside and LPS.  
_________________________________________________________________________ 
       Fall in coronary perfusion pressure       NO release 
  Magnitude (mmHg)  Duration (min)  NO (pmol.g-1.min-
1) 
_________________________________________________________________________ 
Control: 
 
 LPS          34 ± 3         >120        11.6 ± 0.8 
 
 BK           43 ± 2         8 ± 1   ND 
 
 SNP           43 ± 2         8 ± 0.3   ND 
 
 
 
L-NAME: 
 
 LPS            0 ± 5*    0           <MDL 
 
 BK           30 ± 3         3 ± 2*   ND 
 
 SNP           37 ± 3       11 ± 2   ND 
 
 
 
_________________________________________________________________________ 
 
Hearts were perfused as described in the methods and PP elevated with 5 nM U46619 
(control) or 50 μM L-NAME (n=3). Responses were recorded to 10 μl bolus injections of 0.1 
nmol BK (n=3) and 10 nmol SNP (n=3), or infusion of 5 μg.ml-1 LPS (n=3). In parallel 
studies, flow was reduced to 1 ml.min-1 and NO release due to LPS-treatment measured by 
chemiluminescent detection. ND denotes not determined, <MDL denotes below minimum 
detection limit, * denotes statistical significance at P<0.01  compared to respective controls. 
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Table 2. Effects of mepacrine, WEB 2086 and NDGA on vasodilator responses to 
bradykinin, sodium nitroprusside and LPS. 
___________________________________________________________________________ 
                 Fall in coronary perfusion pressure (mmHg) 
 
    Bradykinin  sodium nitroprussside      LPS 
    (0.1 nmol)           (10 nmol)  (5 μg.ml-1) 
___________________________________________________________________________ 
 
Control   39 ± 3    29 ± 4       59 ± 4 
Mepacrine (0.5 μM) 30 ± 2    31 ± 3         3 ± 4* 
 
 
Control   45 ± 9    34 ± 8       59 ± 4  
WEB 2086 (3 μM)  52 ± 7    25 ± 4       17 ± 5*  
 
 
Control   53 ± 10   61 ± 11      59 ± 4   
NDGA (0.1 μM)  52 ± 10   51 ± 10        9 ± 3* 
 
___________________________________________________________________________ 
 
 
Hearts were perfused as in methods. Responses to bradykinin (BK; 0.1 nmol), sodium 
nitroprusside (SNP; 10 nmol) or LPS (5 μg.ml-1) were obtained prior to (control) and 
following a 30 min pre-perfusion of hearts with either mepacrine (0.5 μM; n=3), WEB 
2086 (3 μM; n=4) or NDGA (0.1 μM; n=4). *denotes statistical significance at P<0.01 
compared to respective controls. 
 
 
 
